Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

PrEP science news


From To
CytoDyn Signs Groundbreaking Memorandum of Understanding with Thai Red Cross AIDS Research Centre to Study Pre-Exposure Prophylaxis Use of Leronlimab (PRO 140) in People at High Risk of Acquiring HIV

“The rationale for the use of leronlimab as PrEP is grounded in the long-standing observation that individuals deficient for the CCR5 co-receptor are nearly completely resistant to sexual transmission of HIV,” said Dr. Jonah Sacha, Associate Professor of the Oregon Health & Science University. Dr. Sacha continued, “Given the difficulties many patients face with adherence to daily oral antiretroviral therapy drugs as PrEP, once-weekly leronlimab as PrEP could be transformative in slowing the epidemic.”

20 June 2019
CytoDyn press release
Truvada as PrEP Tied to Only Modest Bone Density Decline

A new analysis also found a correlation between higher adherence to the daily drug regimen and greater bone density loss.

17 June 2019
Study Suggests Widespread PrEP Use Would Take a Big Bite Out of HIV

The study also projected that PrEP use among adult gay and bi men would result in considerable reductions of HIV among adolescents.

11 June 2019
Is Off-Label HIV Prevention Better Than None?

Rather than prescribe F/TDF as PrEP, Michael Saag, MD said, prescribers should sidestep the brand-name product and instead give their PrEP-eligible patients a generic HIV drug combination that uses lamivudine (3TC) with TDF.

31 May 2019
MedPage Today (requires free registration)
New Zealand: The tide turns on HIV

The goal to virtually eliminate HIV transmission in NZ by 2025 suddenly looks attainable. Dr Peter Saxon explains why.

17 May 2019
Some people may have genes that hamper a drug's HIV protection

Some people’s genes may stop an antiretroviral drug from protecting them against HIV, a genetics study suggests.

13 May 2019
Science News
Do Feminizing Hormones Impact Efficacy of PrEP Drugs?

A team of investigators is examining why some transgender women taking hormones may need higher levels of PrEP medication.

29 April 2019
Contagion Live
PrEP May Offer Psychological Benefits to Gay, Bisexual Men at Risk for HIV

A new study has identified lower rates of sexual anxiety among gay and bisexual men taking pre-exposure prophylaxis (PrEP).

24 April 2019
American Journal of Managed Care
Letter to FDA Regarding Application for Descovy as Pre-Exposure Prophylaxis for HIV

TAG and PrEP4All sent this letter to Dr. Debra Birnkrant of the FDA, outlining and expressing our serious concerns about Gilead’s supplemental New Drug Application for Descovy (FTC/TAF) as HIV-1 preexposure prophylaxis (PrEP). There are several specific recommendations in the letter for this approval process, including recomending that the FDA convene a public meeting of the Antiviral Drug Advisory Committee.

17 April 2019
Treatment Action Group
Sticker Shock: PrEP Is Not Cost-Effective at Current Price, Health Economists Find

For years, the U.S. HIV prevention community has known that pre-exposure prophylaxis (PrEP) is prohibitively expensive for many patients who need it. Now, new research presented at the 2019 National HIV Prevention Conference (NHPC) in Atlanta finds that not only is PrEP expensive for individual patients, it's also not cost-effective for the health system as a whole.

09 April 2019
The Body
← First12345...16Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.